Compare TG Therapeutics Inc (TGTX) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Uber Technologies Inc — how do they compare? TG Therapeutics Inc trades at $50.5 (market cap $7.64B), while Uber Technologies Inc trades at $76.36 (market cap $160.42B). The key difference: Uber Technologies Inc is far larger — about 21× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | UBER | |
|---|---|---|
Market Cap | $7.64B | $160.42B |
Sector | Health | Industrials |
52-Week High | $59.06 | $100.10 |
52-Week Low | $26.94 | $65.94 |
Enterprise Value | $7.84B | $169.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
Uber (UBER) trades at $78.03, up 4.01% today, with strong bullish technical signals and robust fundamentals including 2025 revenue of $52.02B and net income of $10.05B. Recent news highlights expansion in autonomous vehicle partnerships, such as the robotaxi pilot in Madrid with WeRide, while the company streamlines operations with HR layoffs and implements AI spending caps to manage costs.
The outlook remains positive with a consensus price target of $102.88, representing significant upside, driven by earnings beats and strategic initiatives in autonomous mobility. Key risks include competitive pressures in ride-hailing, regulatory scrutiny, and execution challenges in new technology deployments that could impact growth and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
